Variations in radioiodine ablation: decision-making after total thyroidectomy.
Decision Making
Radioiodine
Thyroidectomy
Treatment
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
05
2019
accepted:
25
09
2019
pubmed:
11
11
2019
medline:
15
5
2021
entrez:
11
11
2019
Statut:
ppublish
Résumé
The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today. We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
Sections du résumé
BACKGROUND
The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.
METHODS
We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
Identifiants
pubmed: 31707428
doi: 10.1007/s00259-019-04557-4
pii: 10.1007/s00259-019-04557-4
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-560Références
Oncologist. 2015 Sep;20(9):1028-35
pubmed: 26240132
J Nucl Med. 2018 Aug;59(8):1187-1194
pubmed: 29653980
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
Clin Colorectal Cancer. 2019 Dec;18(4):e335-e342
pubmed: 31371166
Swiss Med Wkly. 2019 Jan 27;149:w14700
pubmed: 30685866
BMC Urol. 2018 Apr 10;18(1):25
pubmed: 29636048
BMC Med Res Methodol. 2017 Aug 16;17(1):123
pubmed: 28814269
J Neurol. 2019 Aug;266(8):2010-2017
pubmed: 31104135
J Clin Endocrinol Metab. 2004 Aug;89(8):3668-76
pubmed: 15292285
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1001-5
pubmed: 26883666
J Surg Oncol. 2006 Dec 15;94(8):692-700
pubmed: 17131429
Thyroid. 2019 Apr;29(4):461-470
pubmed: 30900516
J Neurooncol. 2016 Jan;126(1):175-183
pubmed: 26459327
Clin Endocrinol (Oxf). 2017 Nov;87(5):411-417
pubmed: 28666074
Thyroid. 2010 Nov;20(11):1235-45
pubmed: 21062195
Radiat Oncol. 2014 Dec 05;9:270
pubmed: 25476988
Surgery. 2008 Dec;144(6):980-7; discussion 987-8
pubmed: 19041007
Nuklearmedizin. 2016 Jun 28;55(3):77-89
pubmed: 27350004
Cancer. 2017 Feb 1;123(3):372-381
pubmed: 27741354
JAMA. 2006 May 10;295(18):2164-7
pubmed: 16684987
J Med Internet Res. 2013 Sep 19;15(9):e207
pubmed: 24052454
Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8
pubmed: 8256208
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59
pubmed: 18670773
Strahlenther Onkol. 2015 Oct;191(10):778-86
pubmed: 25986251
Surgery. 1988 Dec;104(6):947-53
pubmed: 3194846
J Nucl Med. 2018 Aug;59(8):1195-1201
pubmed: 29748234
Radiother Oncol. 2019 Jun;135:74-77
pubmed: 31015173
Surgery. 1987 Dec;102(6):1088-95
pubmed: 3686348
J Clin Endocrinol Metab. 2012 May;97(5):1526-35
pubmed: 22344193
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2004 Jun;14(6):453-8
pubmed: 15242573